The global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market size was estimated at USD 1120 million in 2024 and is projected to reach USD 1990.82 million by 2032, exhibiting a CAGR of 6.60% during the forecast period.
North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market size was estimated at USD 325.79 million in 2024, at a CAGR of 5.66% during the forecast period of 2025 through 2032.
Report Overview
Non-alcoholic steatohepatitis (NASH) is a form of liver disease characterized by inflammation and liver cell damage caused by the accumulation of fat in the liver. It is often associated with obesity, insulin resistance, and metabolic syndrome. As there is currently no approved specific therapy for NASH, treatment primarily focuses on managing the underlying risk factors and minimizing liver damage.
This report provides a deep insight into the global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market in any manner.
Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Allergan plc
- Pfizer Inc
- Gilead Sciences
- Genfit SA
- Novartis AG
- Intercepts Pharmaceuticals
- Cadila Healthcare
- Novo Nordisk
- Raptor Pharmaceutical Corp
- Galmed Pharmaceuticals
- Madrigal Pharmaceuticals
- Viking Therapeutics
- Conatus Pharmaceuticals
- NGM Biopharmaceuticals
- CymaBay Therapeutics
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
Market Segmentation (by Type)
- Imaging Techniques
- Diagnostic Tests
- Biopsy
- Others
Market Segmentation (by Application)
- Hospital Pharmacy
- Online Channels
- Retail Channels
- Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market
- Overview of the regional outlook of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
1.2 Key Market Segments
1.2.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Segment by Type
1.2.2 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Overview
2.1 Global Market Overview
2.1.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Competitive Landscape
3.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Manufacturers (2019-2025)
3.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Manufacturers (2019-2025)
3.3 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Sites, Area Served, Product Type
3.6 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Competitive Situation and Trends
3.6.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Industry Chain Analysis
4.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Type (2019-2025)
6.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Market Share by Type (2019-2025)
6.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price by Type (2019-2025)
7 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Sales by Application (2019-2025)
7.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) by Application (2019-2025)
7.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2025)
8 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Consumption by Region
8.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.1.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Production by Region
9.1 Global Production of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Region (2019-2025)
9.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Region (2019-2025)
9.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production
9.4.1 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Growth Rate (2019-2025)
9.4.2 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production
9.5.1 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Growth Rate (2019-2025)
9.5.2 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (2019-2025)
9.6.1 Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Growth Rate (2019-2025)
9.6.2 Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (2019-2025)
9.7.1 China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Growth Rate (2019-2025)
9.7.2 China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Allergan plc
10.1.1 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.1.2 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.1.3 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.1.4 Allergan plc Business Overview
10.1.5 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
10.1.6 Allergan plc Recent Developments
10.2 Pfizer Inc
10.2.1 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.2.2 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.2.3 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.2.4 Pfizer Inc Business Overview
10.2.5 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
10.2.6 Pfizer Inc Recent Developments
10.3 Gilead Sciences
10.3.1 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.3.2 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.3.3 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.3.4 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
10.3.5 Gilead Sciences Business Overview
10.3.6 Gilead Sciences Recent Developments
10.4 Genfit SA
10.4.1 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.4.2 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.4.3 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.4.4 Genfit SA Business Overview
10.4.5 Genfit SA Recent Developments
10.5 Novartis AG
10.5.1 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.5.2 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.5.3 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.5.4 Novartis AG Business Overview
10.5.5 Novartis AG Recent Developments
10.6 Intercepts Pharmaceuticals
10.6.1 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.6.2 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.6.3 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.6.4 Intercepts Pharmaceuticals Business Overview
10.6.5 Intercepts Pharmaceuticals Recent Developments
10.7 Cadila Healthcare
10.7.1 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.7.2 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.7.3 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.7.4 Cadila Healthcare Business Overview
10.7.5 Cadila Healthcare Recent Developments
10.8 Novo Nordisk
10.8.1 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.8.2 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.8.3 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.8.4 Novo Nordisk Business Overview
10.8.5 Novo Nordisk Recent Developments
10.9 Raptor Pharmaceutical Corp
10.9.1 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.9.2 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.9.3 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.9.4 Raptor Pharmaceutical Corp Business Overview
10.9.5 Raptor Pharmaceutical Corp Recent Developments
10.10 Galmed Pharmaceuticals
10.10.1 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.10.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.10.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.10.4 Galmed Pharmaceuticals Business Overview
10.10.5 Galmed Pharmaceuticals Recent Developments
10.11 Madrigal Pharmaceuticals
10.11.1 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.11.2 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.11.3 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.11.4 Madrigal Pharmaceuticals Business Overview
10.11.5 Madrigal Pharmaceuticals Recent Developments
10.12 Viking Therapeutics
10.12.1 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.12.2 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.12.3 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.12.4 Viking Therapeutics Business Overview
10.12.5 Viking Therapeutics Recent Developments
10.13 Conatus Pharmaceuticals
10.13.1 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.13.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.13.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.13.4 Conatus Pharmaceuticals Business Overview
10.13.5 Conatus Pharmaceuticals Recent Developments
10.14 NGM Biopharmaceuticals
10.14.1 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.14.2 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.14.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.14.4 NGM Biopharmaceuticals Business Overview
10.14.5 NGM Biopharmaceuticals Recent Developments
10.15 CymaBay Therapeutics
10.15.1 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.15.2 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.15.3 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.15.4 CymaBay Therapeutics Business Overview
10.15.5 CymaBay Therapeutics Recent Developments
10.16 Boehringer Ingelheim
10.16.1 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.16.2 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.16.3 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.16.4 Boehringer Ingelheim Business Overview
10.16.5 Boehringer Ingelheim Recent Developments
10.17 Eli Lilly and Company
10.17.1 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.17.2 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.17.3 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.17.4 Eli Lilly and Company Business Overview
10.17.5 Eli Lilly and Company Recent Developments
10.18 Bristol Myers Squibb
10.18.1 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
10.18.2 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
10.18.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
10.18.4 Bristol Myers Squibb Business Overview
10.18.5 Bristol Myers Squibb Recent Developments
11 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Region
11.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast
11.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country
11.2.3 Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region
11.2.4 South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2025-2032)
12.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2025-2032)
12.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Application (2025-2032)
12.2.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) Forecast by Application
12.2.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Comparison by Region (M USD)
Table 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Manufacturers (2019-2025)
Table 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics as of 2022)
Table 10. Global Market Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Sites and Area Served
Table 12. Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Type
Table 13. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Challenges
Table 22. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Type (K Units)
Table 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Type (M USD)
Table 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Type (2019-2025)
Table 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Type (2019-2025)
Table 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) by Type (2019-2025)
Table 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Share by Type (2019-2025)
Table 28. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price (USD/Unit) by Type (2019-2025)
Table 29. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Application
Table 30. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Application
Table 31. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Application (2019-2025) & (K Units)
Table 32. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application (2019-2025)
Table 33. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Application (2019-2025) & (M USD)
Table 34. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application (2019-2025)
Table 35. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2025)
Table 36. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2025) & (K Units)
Table 37. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region (2019-2025)
Table 38. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2025) & (K Units)
Table 39. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2025) & (K Units)
Table 40. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2025) & (K Units)
Table 41. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2025) & (K Units)
Table 42. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2025) & (K Units)
Table 43. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) by Region (2019-2025)
Table 44. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Region (2019-2025)
Table 46. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 47. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 48. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 49. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 50. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 51. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 52. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 53. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 54. Allergan plc Business Overview
Table 55. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 56. Allergan plc Recent Developments
Table 57. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 58. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 59. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 60. Pfizer Inc Business Overview
Table 61. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 62. Pfizer Inc Recent Developments
Table 63. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 64. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 65. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 66. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis
Table 67. Gilead Sciences Business Overview
Table 68. Gilead Sciences Recent Developments
Table 69. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 70. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 71. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 72. Genfit SA Business Overview
Table 73. Genfit SA Recent Developments
Table 74. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 75. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 76. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 77. Novartis AG Business Overview
Table 78. Novartis AG Recent Developments
Table 79. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 80. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 81. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 82. Intercepts Pharmaceuticals Business Overview
Table 83. Intercepts Pharmaceuticals Recent Developments
Table 84. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 85. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 86. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 87. Cadila Healthcare Business Overview
Table 88. Cadila Healthcare Recent Developments
Table 89. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 90. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 91. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 92. Novo Nordisk Business Overview
Table 93. Novo Nordisk Recent Developments
Table 94. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 95. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 96. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 97. Raptor Pharmaceutical Corp Business Overview
Table 98. Raptor Pharmaceutical Corp Recent Developments
Table 99. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 100. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 101. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 102. Galmed Pharmaceuticals Business Overview
Table 103. Galmed Pharmaceuticals Recent Developments
Table 104. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 105. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 106. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 107. Madrigal Pharmaceuticals Business Overview
Table 108. Madrigal Pharmaceuticals Recent Developments
Table 109. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 110. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 111. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 112. Viking Therapeutics Business Overview
Table 113. Viking Therapeutics Recent Developments
Table 114. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 115. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 116. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 117. Conatus Pharmaceuticals Business Overview
Table 118. Conatus Pharmaceuticals Recent Developments
Table 119. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 120. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 121. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 122. NGM Biopharmaceuticals Business Overview
Table 123. NGM Biopharmaceuticals Recent Developments
Table 124. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 125. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 126. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 127. CymaBay Therapeutics Business Overview
Table 128. CymaBay Therapeutics Recent Developments
Table 129. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 130. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 131. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 132. Boehringer Ingelheim Business Overview
Table 133. Boehringer Ingelheim Recent Developments
Table 134. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 135. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 136. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 137. Eli Lilly and Company Business Overview
Table 138. Eli Lilly and Company Recent Developments
Table 139. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
Table 140. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
Table 141. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 142. Bristol Myers Squibb Business Overview
Table 143. Bristol Myers Squibb Recent Developments
Table 144. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Region (2025-2032) & (K Units)
Table 145. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region (2025-2032) & (M USD)
Table 146. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2032) & (K Units)
Table 147. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)
Table 148. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2032) & (K Units)
Table 149. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)
Table 150. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Region (2025-2032) & (K Units)
Table 151. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region (2025-2032) & (M USD)
Table 152. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2032) & (K Units)
Table 153. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)
Table 154. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Consumption Forecast by Country (2025-2032) & (Units)
Table 155. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)
Table 156. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Type (2025-2032) & (K Units)
Table 157. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Type (2025-2032) & (M USD)
Table 158. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price Forecast by Type (2025-2032) & (USD/Unit)
Table 159. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) Forecast by Application (2025-2032)
Table 160. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD), 2019-2032
Figure 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) (2019-2032)
Figure 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Country (M USD)
Figure 11. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Share by Manufacturers in 2023
Figure 12. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Share by Manufacturers in 2023
Figure 13. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Type
Figure 18. Sales Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2019-2025)
Figure 19. Sales Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type in 2023
Figure 20. Market Size Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2019-2025)
Figure 21. Market Size Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application
Figure 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application (2019-2025)
Figure 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application in 2023
Figure 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application (2019-2025)
Figure 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application in 2023
Figure 28. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2025)
Figure 29. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region (2019-2025)
Figure 30. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 31. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 32. U.S. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 33. Canada Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) and Growth Rate (2019-2025)
Figure 34. Mexico Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 36. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 37. Germany Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 38. France Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 39. U.K. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 40. Italy Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 41. Russia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 42. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 44. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 45. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 46. South Korea Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 47. India Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 49. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 50. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023
Figure 51. Brazil Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 52. Argentina Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 53. Columbia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 57. UAE Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 58. Egypt Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 59. Nigeria Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 60. South Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2025) & (K Units)
Figure 61. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Market Share by Region (2019-2025)
Figure 62. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) Growth Rate (2019-2025)
Figure 63. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) Growth Rate (2019-2025)
Figure 64. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) Growth Rate (2019-2025)
Figure 65. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) Growth Rate (2019-2025)
Figure 66. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Forecast by Type (2025-2032)
Figure 70. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Application (2025-2032)
Figure 71. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Forecast by Application (2025-2032)
